Interventional cardiology devices market seen reaching $21.76 billion by 2030

The interventional cardiology devices and equipment market is projected to grow from $16.46 billion in 2026 to $21.76 billion by 2030, driven by rising cardiovascular disease, minimally invasive procedures and new catheter-based technologies. North America led the market in 2025 as the industry shifts toward AI-assisted care, imaging-guided interventions and patient-specific therapies.

Why it matters: - The market sits at the center of heart-disease treatment, where demand rises as cardiovascular cases increase worldwide. - Growth in minimally invasive care could expand access to procedures that reduce recovery time and surgical risk. - The forecast signals continued investment in stents, catheters and imaging-guided systems used in cardiac interventions.

What happened: - The Business Research Company released its Interventional Cardiology Devices And Equipment Market Report 2026 on Aug. 12, 2026. - The report values the market at $16.46 billion in 2026, up from $15.65 billion in 2025. - The report projects the market will reach $21.76 billion by 2030. - The report estimates a 5.2% compound annual growth rate for 2025-2026 and a 7.2% CAGR through 2030. - North America held the largest share of the global market in 2025. - Western Europe ranked second, followed by Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa.

The details: - Interventional cardiology devices are specialized tools used for minimally invasive heart procedures. - Common products include stents, catheters and guidewires. - These devices are used in procedures such as angioplasty and stent placement. - The market’s historical growth has been supported by higher cardiovascular disease prevalence, broader use of minimally invasive treatment, more cardiac catheterization labs, advances in stent and catheter materials, and population aging. - The report says future growth will be driven by demand for next-generation interventional devices, greater use of AI-assisted cardiac procedures, expansion of outpatient and ambulatory cardiac care, more patient-specific therapies, and higher investment in cardiovascular research and innovation. - The report expects wider adoption of drug-eluting and bioabsorbable stents, more advanced catheter-based therapies, imaging-guided interventions, more minimally invasive cardiac procedures and greater emphasis on precision and patient safety. - The report’s enhanced 2026 market format includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis, and updated graphics and tables. - A free sample is available here. - The full report is available here.

Between the lines: - The growth outlook reflects a broader shift toward less invasive cardiovascular treatment as health systems look for faster procedures and better outcomes. - The emphasis on AI, imaging and precision medicine suggests the market is moving from basic device expansion to more data-driven care. - Cardiovascular disease remains the clearest demand driver, and the report uses Australia as an example of the burden: heart and vascular disease accounted for nearly 12% of total disease burden in 2024. - In Australia, prevalence reached 14% among males and 10% among females, and the country lost an estimated 685,000 healthy life years, equal to 25.5 years lost per 1,000 population.

What's next: - Market growth will likely track cardiovascular disease rates, adoption of outpatient cardiac care and uptake of newer devices. - The strongest opportunities appear to be in drug-eluting stents, bioabsorbable stents, catheter-based therapies and imaging-guided procedures. - Continued research spending and product innovation should shape competition through 2030.

The bottom line: - Interventional cardiology is moving toward faster, more precise and less invasive treatment, and the market is expected to keep growing as heart disease remains a major global health burden.